Crohn’s Disease: Harnessing Gut Microbiome Modulation to Cater to Unmet Needs

Read | Jul 07, 2023

Download Industry Research

AUTHOR(s)

A WNS Perspective

Key Points

Crohn’s disease, an Inflammatory Bowel Disease (IBD) that is complex, idiopathic, progressive and destructive, has an unknown etiology. The several factors causing it (including the immune system) must be considered in three primary contexts: environment, genetics and gut microbiota.

Modern Crohn’s disease treatments either target specific cytokines in the inflammatory cascade or use systemic immunomodulation as their mechanism of action. Despite the introduction of several new classes of biologic therapy – including the Janus Kinase (JAK) inhibitor and upadacitinib – Tumor Necrosis Factor (TNF) antagonists still play a central role in the treatment of moderate-to-severe Crohn's disease.

Comparative analysis by WNS of the efficacy profiles of these therapies suggests that infliximab consistently ranks high when it comes to the induction of clinical response and clinical remission. However, the induced response is rarely maintained for longer than a year. Furthermore, while biologics are the primary treatment option for patients with Crohn's disease, these therapies are not universally effective and have the potential for adverse events. Recent research suggests that targeting other pathways, either alone or in combination with an immune pathway, is needed to control the disease better.

In this regard, gut microbiota forms a promising area for exploration. The gut microbiome has been linked to the development and perseverance of IBD. There is now emerging interest in treatments that positively impact the gut microbiome. This could be an effective approach to Crohn’s treatment and prevention.

Various pharmaceutical companies have already entered the market to investigate and develop treatments centered on a microbiome modulation strategy. While some, like Genentech, have taken their first step and entered a strategic collaboration to discover, develop and commercialize biomarkers, targets and medicines for IBD, other smaller companies already have novel assets, including microbiome modulators, in early clinical testing phases.

To address ongoing changes in the clinical, commercial and regulatory landscape, pharmaceutical companies must adopt a game plan that bolsters their operating models and opens up new avenues for exploration. An effective strategic collaboration is required with a domain specialist with expertise in competitive intelligence and clinical research support to fundamentally improve decision-making with sharp and forward-looking insights.

Download our paper to know more about this competitive sector and the value of partnering with an experienced research team.

FAQs

1. Why is gut microbiome modulation becoming a strategic focus for Crohn's disease drug development?

Growing evidence suggests that gut microbiome imbalance plays a significant role in Crohn's disease progression and treatment response. While biologics remain the standard of care, many patients experience inadequate or diminishing responses, creating demand for innovative therapies that target the microbiome alongside immune pathways. WNS helps life sciences organizations monitor emerging microbiome research, competitive pipelines and clinical developments to support evidence-based R&D and commercialization strategies.

2. How can pharmaceutical companies identify high-potential opportunities in the evolving Crohn's disease treatment landscape?

The Crohn's disease market is rapidly evolving with advances in microbiome therapeutics, precision medicine, biomarker discovery and combination therapies. Organizations need continuous competitive intelligence and scientific monitoring to identify promising assets, partnership opportunities and market shifts early. WNS enables pharmaceutical companies with advanced competitive intelligence, clinical landscape assessments and strategic analytics that improve portfolio and investment decisions.

3. How can AI and advanced analytics accelerate microbiome research in inflammatory bowel disease?

AI and advanced analytics help researchers analyze complex microbiome, genomic and clinical datasets to identify disease biomarkers, predict treatment response and uncover novel therapeutic targets. These capabilities accelerate hypothesis generation, optimize clinical trial strategies and improve research productivity. WNS combines life sciences expertise with AI-driven analytics to help organizations generate faster, data-driven insights across the drug development lifecycle.

4. What challenges do life sciences organizations face when developing microbiome-based therapies for Crohn's disease?

Developing microbiome-based therapies involves scientific, regulatory and commercial challenges, including patient variability, biomarker validation, clinical trial design, manufacturing complexity and long-term efficacy assessment. Success requires integrated clinical intelligence, competitive benchmarking and evidence-based decision-making. WNS supports pharmaceutical companies through scientific intelligence, market landscape analysis and clinical research support that reduces uncertainty and accelerates innovation.

5. Why should pharmaceutical companies partner with WNS for competitive intelligence and clinical research in inflammatory bowel disease?

WNS combines deep life sciences expertise with competitive intelligence, clinical research support, AI-enabled analytics and strategic market assessment capabilities. From therapy landscape monitoring and pipeline intelligence to biomarker analysis and commercialization insights, WNS helps pharmaceutical organizations make faster, more informed decisions that improve R&D productivity and strengthen competitive positioning in emerging therapeutic areas such as Crohn's disease.